In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reprotect Buffergel Phase II Data May Serve As Basis For NDA

This article was originally published in The Tan Sheet

Executive Summary

Data from a Phase II study on the contraceptive efficacy of Reprotect's Buffergel polyacrylic acid may serve as the basis for an eventual NDA filing by the firm. A Phase II trial of the gel's efficacy in preventing pregnancy may begin within the next six months.

You may also be interested in...



Vaginal Lubricants’ Ability To Kill HIV Merits Human Study – Researchers

Clinical trials testing the protective effect of three FDA-approved vaginal lubricants and preparations against HIV should be conducted in populations at high-risk for contracting the virus, University of Texas Medical Branch at Galveston researchers state

Vaginal Lubricants’ Ability To Kill HIV Merits Human Study – Researchers

Clinical trials testing the protective effect of three FDA-approved vaginal lubricants and preparations against HIV should be conducted in populations at high-risk for contracting the virus, University of Texas Medical Branch at Galveston researchers state

Vaginal Lubricants’ Ability To Kill HIV Merits Human Study – Researchers

Clinical trials testing the protective effect of three FDA-approved vaginal lubricants and preparations against HIV should be conducted in populations at high-risk for contracting the virus, University of Texas Medical Branch at Galveston researchers state

Topics

UsernamePublicRestriction

Register

PS089690

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel